Table 4.
Demographic characteristics of interferon-treated cohort.
| Whole cohort | Failed to achieve SVR | Achieved SVR | |
|---|---|---|---|
| n | 85 | 47 | 38 |
| Age (years, mean ± SD) | 52.3 ± 8.8 | 55.0 ± 8.9 | 49.7 ± 7.6 |
| Sex (% male) | 75.3 | 72.3 | 78.9 |
| BMI | 26.6 ± 5.3 | 27.5 ± 5.7 | 25.5 ± 4.5 |
| Bilirubin (μmol/L, mean ± SD) | 12.3 ± 6.6 | 12.2 ± 6.1 | 11.5 ± 6.8 |
| ALT (IU/L, mean ± SD) | 113.2 ± 81.9 | 112.7 ± 83.2 | 117.1 ± 85.7 |
| PT (seconds, mean ± SD) | 13.2 ± 1.4 | 13.2 ± 1.1 | 13.2 ± 1.7 |
| Genotype 1 | 45.9% | 53.2% | 36.8% |
| 2 | 11.8% | 10.6% | 13.2% |
| 3 | 41.2% | 36.2% | 47.4% |
| 4 | 1.1% | 0% | 2.6% |
| Viral Load (mean ± SD) | 1.35 × 106 ± 6.99 × 106 | 2.31 × 10 6 ± 9.34 × 106 | 1.67 × 105 ± 2.54 × 105 |
| % CMV antibody positive | 51.0 | 51.1 | 50.0 |
| Ishak score | |||
| Interface hepatitis (0 - 4) | 1.8 ± 0.6 | 1.7 ± 0.5 | 1.8 ± 0.7 |
| Confluent necrosis (0 - 6) | 0.1 ± 0.2 | 0.1 ± 0.3 | 0.0 ± 0.2 |
| Lobular hepatitis (0 - 4) | 2.2 ± 0.6 | 1.0 ± 0.5 | 2.3 ± 0.6 |
| Portal inflammation (0 - 4) | 2.2 ± 0.6 | 2.2 ± 0.6 | 2.2 ± 0.6 |
| Fibrosis (0 - 6) | 3.6 ± 1.5 | 3.9 ± 1.4 | 3.4 ± 1.5 |
| Steatosis (0 - 3) | 0.8 ± 0.8 | 1.0 ± 0.8 | 0.6 ± 0.8 |